AI promises to be a transformative force in healthcare, but only if it prioritizes the human-first pursuit of improving healthcare outcomes for all.
AI is reshaping healthcare, in developmental processes and decision-making. This whitepaper will provide a wide-lens look at the state of AI in the biopharma industry and the best practices for integrating it into drug development and strategic planning while prioritizing ethical standards of equity and accessibility.
Topics covered within the whitepaper include:
Background on the biopharmaceutical industry, the types of emerging AI technologies and the role of computer models in drug discovery
The benefits and challenges of leveraging AI in early-stage research
The benefits and challenges of integrating AI into strategic planning and medical affairs teams
The ethical considerations in AI-driven pharma research, emphasizing the existing biases and systems that will be exacerbated by AI technology if it is not integrated with equity and ethics as a top priority